Orchestra Biomed Holdings Inc (OBIO)

$7

+0.03

(+0.43%)

Market is closed - opens 7 PM, 30 May 2024

Insights on Orchestra Biomed Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 262.0K → 620.0K (in $), with an average increase of 57.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -12.81M → -13.46M (in $), with an average decrease of 5.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 64.5% return, outperforming this stock by 118.1%

Performance

  • $6.48
    $7.26
    $7.00
    downward going graph

    7.43%

    Downside

    Day's Volatility :10.74%

    Upside

    3.58%

    downward going graph
  • $4.22
    $17.35
    $7.00
    downward going graph

    39.71%

    Downside

    52 Weeks Volatility :75.68%

    Upside

    59.65%

    downward going graph

Returns

PeriodOrchestra Biomed Holdings IncIndex (Russel 2000)
3 Months
8.23%
0.0%
6 Months
12.24%
0.0%
1 Year
-51.86%
0.0%
3 Years
-39.39%
-22.0%

Highlights

Market Capitalization
226.9M
Book Value
$1.6
Earnings Per Share (EPS)
-1.46
Wall Street Target Price
16.33
Profit Margin
0.0%
Operating Margin TTM
-2326.29%
Return On Assets TTM
-31.05%
Return On Equity TTM
-65.81%
Revenue TTM
2.2M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-46.7%
Gross Profit TTM
0.0
EBITDA
-54.1M
Diluted Eps TTM
-1.46
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.54
EPS Estimate Next Year
-1.54
EPS Estimate Current Quarter
-0.4
EPS Estimate Next Quarter
-0.4

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Orchestra Biomed Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 133.29%

Current $7.00
Target $16.33

Company Financials

FY20Y/Y Change
Revenue
5.7M
-
Net Income
-21.4M
-
Net Profit Margin
-374.45%
-
FY21Y/Y Change
Revenue
-782.0K
↓ 113.71%
Net Income
-23.0M
↑ 7.77%
Net Profit Margin
2.9K%
↑ 3317.42%
FY22Y/Y Change
Revenue
3.5M
↓ 551.79%
Net Income
-33.6M
↑ 46.03%
Net Profit Margin
-951.26%
↓ 3894.23%
FY23Y/Y Change
Revenue
2.8M
↓ 21.88%
Net Income
-49.1M
↑ 46.16%
Net Profit Margin
-1.8K%
↓ 828.45%
Q4 FY22Q/Q Change
Revenue
1.1M
↓ 5.16%
Net Income
-876.7K
↑ 27.84%
Net Profit Margin
-79.49%
↓ 20.52%
Q1 FY23Q/Q Change
Revenue
1.2M
↑ 5.53%
Net Income
-10.9M
↑ 1147.83%
Net Profit Margin
-939.86%
↓ 860.37%
Q2 FY23Q/Q Change
Revenue
915.0K
↓ 21.39%
Net Income
-12.0M
↑ 10.11%
Net Profit Margin
-1.3K%
↓ 376.64%
Q3 FY23Q/Q Change
Revenue
419.0K
↓ 54.21%
Net Income
-13.3M
↑ 10.54%
Net Profit Margin
-3.2K%
↓ 1861.54%
Q4 FY23Q/Q Change
Revenue
262.0K
↓ 37.47%
Net Income
-12.8M
↓ 3.74%
Net Profit Margin
-4.9K%
↓ 1714.33%
Q1 FY24Q/Q Change
Revenue
620.0K
↑ 136.64%
Net Income
-13.5M
↑ 5.03%
Net Profit Margin
-2.2K%
↑ 2720.92%
FY20Y/Y Change
Total Assets
38.1M
-
Total Liabilities
86.6M
-
FY21Y/Y Change
Total Assets
13.5M
↓ 64.49%
Total Liabilities
84.8M
↓ 2.16%
FY22Y/Y Change
Total Assets
95.6M
↑ 606.53%
Total Liabilities
43.0M
↓ 49.22%
FY23Y/Y Change
Total Assets
95.2M
↓ 0.38%
Total Liabilities
27.2M
↓ 36.87%
Q4 FY22Q/Q Change
Total Assets
68.1M
↓ 0.84%
Total Liabilities
7.3M
↑ 4.31%
Q1 FY23Q/Q Change
Total Assets
136.3M
↑ 100.19%
Total Liabilities
36.5M
↑ 397.4%
Q2 FY23Q/Q Change
Total Assets
125.9M
↓ 7.63%
Total Liabilities
36.4M
↓ 0.23%
Q3 FY23Q/Q Change
Total Assets
116.4M
↓ 7.57%
Total Liabilities
36.7M
↑ 0.71%
Q4 FY23Q/Q Change
Total Assets
95.2M
↓ 18.17%
Total Liabilities
27.2M
↓ 25.97%
Q1 FY24Q/Q Change
Total Assets
82.6M
↓ 13.22%
Total Liabilities
25.4M
↓ 6.36%
FY20Y/Y Change
Operating Cash Flow
-26.2M
-
Investing Cash Flow
27.0M
-
Financing Cash Flow
10.0M
-
FY21Y/Y Change
Operating Cash Flow
-19.4M
↓ 25.8%
Investing Cash Flow
13.0M
↓ 51.73%
Financing Cash Flow
-4.0M
↓ 139.93%
Q4 FY22Q/Q Change
Operating Cash Flow
-8.7M
↑ 1430.05%
Investing Cash Flow
8.1M
↓ 3724.11%
Financing Cash Flow
-5.1M
↓ 94.5%
Q1 FY23Q/Q Change
Operating Cash Flow
-14.4M
↑ 64.47%
Investing Cash Flow
8.1M
↑ 0.0%
Financing Cash Flow
56.8M
↓ 1216.33%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.5M
↓ 27.06%
Investing Cash Flow
8.1M
↑ 0.0%
Financing Cash Flow
86.0K
↓ 99.85%

Technicals Summary

Sell

Neutral

Buy

Orchestra Biomed Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Orchestra Biomed Holdings Inc
Orchestra Biomed Holdings Inc
58.77%
12.24%
-51.86%
-39.39%
-39.39%
Moderna, Inc.
Moderna, Inc.
37.25%
93.9%
21.76%
-17.04%
605.99%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.04%
20.35%
33.57%
93.38%
216.19%
Novo Nordisk A/s
Novo Nordisk A/s
5.67%
31.45%
67.8%
238.63%
470.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
12.79%
27.32%
37.37%
113.13%
168.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Orchestra Biomed Holdings Inc
Orchestra Biomed Holdings Inc
NA
NA
NA
-1.54
-0.66
-0.31
NA
1.6
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.07
29.07
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
47.24
47.24
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.67
29.67
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Orchestra Biomed Holdings Inc
Orchestra Biomed Holdings Inc
Buy
$226.9M
-39.39%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$63.9B
605.99%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.5B
216.19%
29.07
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$606.0B
470.19%
47.24
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.9B
168.32%
29.67
39.46%

Company Information

Organization
Orchestra Biomed Holdings Inc
Employees
56
CEO
Mr. David P. Hochman
Industry
Miscellaneous

FAQs